Patents by Inventor David Hardern

David Hardern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION
    Publication number: 20150152111
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: June 20, 2014
    Publication date: June 4, 2015
    Applicant: AstraZeneca UK Limited
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON
    Publication number: 20140296258
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: October 31, 2013
    Publication date: October 2, 2014
    Applicant: AstraZeneca UK Limited
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION
    Publication number: 20130072503
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: March 19, 2012
    Publication date: March 21, 2013
    Applicant: AstraZeneca
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Novel compounds
    Publication number: 20120165348
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: July 21, 2011
    Publication date: June 28, 2012
    Applicant: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
    Publication number: 20100069408
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: November 18, 2009
    Publication date: March 18, 2010
    Applicant: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
    Publication number: 20080214812
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: May 8, 2008
    Publication date: September 4, 2008
    Applicant: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Novel compounds
    Publication number: 20070265282
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: February 28, 2007
    Publication date: November 15, 2007
    Applicant: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
    Patent number: 7250419
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: July 31, 2007
    Assignee: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Novel compounds
    Publication number: 20060025590
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: September 21, 2005
    Publication date: February 2, 2006
    Applicant: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Compounds
    Patent number: 6974868
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: December 13, 2005
    Assignee: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Novel compounds
    Publication number: 20030144305
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: December 20, 2002
    Publication date: July 31, 2003
    Applicant: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Triazolo(4,5-d)pyrimidine compounds
    Patent number: 6525060
    Abstract: Triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows: wherein R, X and R1 through R3 are as defined in the specification.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: February 25, 2003
    Assignee: Astrazeneca UK Limited
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Triazolo [4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation
    Patent number: 6156756
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: December 5, 2000
    Assignee: AstraZeneca UK Limited
    Inventors: David Hardern, Brian Springthorpe
  • Pyridine derivatives and pharmaceutical compositions containing them
    Patent number: 6143751
    Abstract: Compounds of the formula (I) wherein X, R.sup.1, R.sup.2, and Ar.sup.1 as defined in the specification. The compounds are useful medicaments, particularly in the treatment of asthma or rhinitis.
    Type: Grant
    Filed: May 11, 1998
    Date of Patent: November 7, 2000
    Assignee: AstraZeneca UK Limited
    Inventors: David Cheshire, David Cladinggboel, Martin Cooper, David Hardern, Simon Hirst, Carol Manners, Michael Stocks
  • Compounds
    Patent number: 5977105
    Abstract: A compound of formula I, ##STR1## wherein--X represents (CH.sub.2).sub.n O, (CH.sub.2).sub.n S or C.sub.2 alkylene;n represents 1 or 2;Ar.sup.1 represents indanyl, tetrahydronaphthyl, naphthyl or phenyl, which latter two groups may be substituted by one or more substituents selected from chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21, C(O)R.sup.2, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), pyridyl, thiazinyl, phenyl or C.sub.7-9 alkylphenyl which latter two groups are optionally substituted by one or more substituent selected from halo, nitro, OR.sup.3, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), C(O)R.sup.4, C(O)OR.sup.5, C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19 and SO.sub.2 NR.sup.17 R.sup.18 ;m represents an integer 1 to 3;R.sup.1, R.sup.2 and R.sup.3 independently represent H, C.sub.
    Type: Grant
    Filed: March 3, 1997
    Date of Patent: November 2, 1999
    Assignee: Astra Pharmaeuticals Ltd.
    Inventors: David Cheshire, David Cladingboel, David Hardern, Michael Stocks